Key result
Targeted RBC extracellular vesicles curb lymphoma progression and prolong survival in preclinical models with reduced toxicity.
Why the study?
An improved, simple, rapid, and accurate HPLC method was needed for quantification of doxorubicin from micelle-encapsulated and liposome-encapsulated formulations in rat plasma to support pharmacokinetic studies.
May inform targeted EV delivery strategies; leaves open clinical translation beyond murine models.
An improved simple, rapid and accurate HPLC method for quantification of doxorubicin derived from micelle-encapsulated or liposome-encapsulated doxorubicin formulation in rat plasma was described. The mobile phase consisting of a mixture of methanol-water [containing 0.1% formic acid anhydrous and 0.1% ammonia solution (25%), pH 3.0], 60:40, was delivered at a flow rate of 1.0 mL/min. Sample preparation for micelle- or liposome-encapsulated doxorubicin in rat plasma were achieved directly by protein precipitation with acetonitrile. Doxorubicin and daunorubicin (internal standard, IS) were separated on a C(18) reversed-phase HPLC column and quantified by a fluoresence detection with an excitation wavelength of 475 nm and an emission wavelength of 580 nm. The linearity was obtained over the range of 5.0-1000.0 ng/mL and 1.0-200.0 microg/mL for doxorubicin and the lower limit of quantitation was 5.0 ng/mL. For each level of quality control samples, inter- and intra-assay precision was less than 9.6 and 5.1% (relative standard deviation), respectively, and percentage error was within +/-2.6%. The extraction recoveries of doxorubicin in the range of 10 ng/mL to 100 microg/mL in rat plasma were between 94.1 and 105.6%. This method was successfully applied to the pharmacokinetic study of doxorubicin formulations after i.v. administration to rats.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2008) studied B cell malignancies (Burkitt lymphoma and B-CLL). gp350-anchored RBC-EVs loaded with doxorubicin or fludarabine vs. Routine dose of doxorubicin or fludarabine, unmodified RBC-EVs was evaluated on Tumor progression and survival. gp350-anchored red blood cell extracellular vesicles loaded with doxorubicin or fludarabine significantly inhibited tumor progression and extended survival in mouse models of Burkitt lymphoma and B-CLL with reduced systemic toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: